Biokin Pharmaceutical Co. Ltd. has selected Cryoport’s full suite of temperature-controlled solutions to support its Phase I and II clinical trials in immuno-oncology in both the US and China.
Biokin Pharma, a biopharmaceutical company based in China, focuses on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates.
The company utilises several technology platforms to develop advanced antibody-based drug therapies, it’s wholly-owned subsidiary Systimmune Inc., was formed to advance its mission in the US.
Partnering with Cryoport will enable Biokin Pharma and Systimmune to utilise Cryoport’s full range of temperature-controlled logistics solutions to support its drug manufacturing processes across the globe. These solutions include Cryoport Express® shippers, the Cryoportal™ Logistics Management Platform, Smartpak II™ Condition Monitoring System and logistics support.
... to continue reading you must be subscribed
